lifestyle.washingtonguardian.com

Author: BriaCell Therapeutics Corp.

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

May 15, 2026
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

May 14, 2026
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

May 13, 2026
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

May 12, 2026
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

May 7, 2026
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

May 6, 2026
BriaCell Announces Six Clinical Data Presentations at ASCO 2026

April 27, 2026
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

April 21, 2026
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

April 20, 2026
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

March 31, 2026